NasdaqGS:DAWNBiotechs
Day One Biopharmaceuticals (DAWN) Is Up 11.7% After Strong OJEMDA 2025 Sales And 2026 Outlook - Has The Bull Case Changed?
In January 2026, Day One Biopharmaceuticals reported preliminary unaudited 2025 net product revenue of about US$155.4 million for OJEMDA, with fourth-quarter sales of roughly US$52.8 million supported by rising prescription volumes.
An interesting angle is that management is guiding 2026 U.S. OJEMDA revenue to a US$225 million–US$250 million range, reinforcing its importance as the company’s primary growth engine while it advances new oncology assets acquired with Mersana.
With OJEMDA’s...